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Abstract 
Circulating tumour cells (CTCs) have significant diagnostic potential as they can reflect both the 
presence and recurrence of a wide range of cancers. However, this potential continues to be limited 
by the lack of robust and accessible isolation technologies. An alternative to isolation might be their 
direct detection amongst other peripheral blood cells, although this would require markers that 
allow them to be distinguished from an exceptionally high background signal. This review assesses 
the potential role of HOX genes, a family of homeodomain containing transcription factors with key 
roles in both embryonic development and oncogenesis, as unique and possibly disease specific 
markers of CTCs. 
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Introduction 
Circulating tumour cells (CTCs) have been identified for a wide range of cancers types, although 
notable examples include breast [1], prostate [2], colorectal [3], and lung cancer [4]. In addition to 
providing a mechanistic explanation for widespread disease dissemination, they also represent a 
potential biomarker for diagnosis and prognosis. Hence, for example in breast cancer the presence 
of CTCs is an independent prognostic factor for both progression-free survival and overall survival, 
and a cut-off of 5 CTCs / 7.5 ml has been used to identify patients with a good or poor prognosis [5]. 
In addition, the persistence of CTCs after adjuvant therapy for breast cancer is significantly 
associated with a shorter disease-free survival. 
 
Although CTCs are a potentially useful biomarker, an intrinsic difficulty of this approach is their 
rarity, and their identification requires a combination of enrichment and detection strategies. The 
latter is based on technologies that can distinguish CTCs from blood cells based on their physical 
(e.g. size, density, electrical charge and deformability), and biological properties (e.g. cell surface 
protein expression and viability). Ficol gradients are one of the simplest and earliest methods used 
to separate CTCs, but other available methods include the use of dielectrophoretic technology to 
exploit differences in the biophysical properties of CTCs and blood cells [6], and label-free chips that 
separate CTCs based on their size [7]. Most techniques used to enrich CTCs are based on the 
expression of distinct cell surface markers that can be immunologically detected. The most 
commonly exploited cell surface marker is the epithelial cell adhesion molecule (EpCam), which is 
central to a range of antigen-capture based techniques such as CellSearch® and CTC-CHIP [8, 9]. 
However, there are no uniformly expressed CTC markers, and EpCam itself is not present on all CTCs, 
most notable because it is down regulated during the epithelial-to-mesenchymal transition, a 
process that is central to metastatic change [10].  
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An alternative to CTC isolation could be the identification of gene expression patterns that are not 
present in blood cells. This would inevitably be complicated by the vast excess of RNA from white 
blood cells in any preparation made from whole blood. However, sensitive detection methods for 
identifying a small number of transcripts, for example quantitative PCR (qPCR), could allow CTCs to 
be identified, as well as potentially the cancer from which they originated, if specific patterns of 
gene expression could be established that are not presented by white blood cells. One particularly 
strong candidate in this respect is the HOX gene family. 
 
HOX genes 
The HOX genes are a family of homedomain-containing transcription factors that have a crucial role 
in the patterning of the early embryo, as well as some more limited functions in adult physiology. 
There are 39 HOX genes in the human genome present in 4 separate genomic clusters, named A-D, 
which arose from a series of duplication events prior to the emergence of mammals [11]. Unusually, 
genes within each cluster share enhancer regions, leading to a closely coordinated pattern of 
expression during development and a close relationship between the position of each HOX gene in 
the cluster and its temporal and spatial expression. Thus, for example, the 3’ most member of the 
HOXB cluster, HOXB1, is expressed earlier and more anteriorly than one of the most 5’ members, 
HOXB9 [12]. HOX proteins have relatively limited specificity for DNA, binding to a 4 base pair 
sequence. Their binding specificity and hence target gene activation (or in some cases repression) is 
greatly enhanced by their interaction with specific co-factors such as PBX and MEIS proteins [13, 14].  
 
During early development, HOX gene products help to define the identity of the tissues in which 
they are expressed, principally along the anterior to posterior axis. These tissues include the nervous 
system posterior to the midbrain, the gut, and the limbs [11]. In addition, some adult cells continue 
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to express HOX genes and in these cells HOX expression is necessary to maintain cellular identity, 
and in some cases is also needed for continued cell proliferation and survival. One of the best 
characterized examples is the hematopoietic stem cell and its differentiated progeny. HOXB4 is 
required for the continued proliferation of hematopoietic stem cells, and once their daughter cells 
subsequently begin to differentiate through the long cascade of hematopoietic progenitor cell types 
they express different HOX genes in nested patterns, with the mature lymphocytes expressing quite 
distinct patterns of HOX genes compared to the parental stem cells [15]. 
 
HOX genes in cancer 
In addition to their function in the embryo and in some normal adult cells, the HOX genes also have a 
key function in malignancy. This has been reviewed extensively elsewhere, but in brief, the HOX 
genes are frequently dysregulated in almost all of the solid and haematological malignancies in 
which they have been studied [16]. A number of them have been shown to function as oncogenes, 
including HOXA9, the forced expression of which in normal mouse bone marrow cells leads to acute 
myeloid leukaemia within 3 months [17]. Many other HOX genes have been shown to have a pro-
oncogenic role in terms of supporting tumour growth. HOX proteins can promote cell proliferation 
and survival through interaction with the PBX co-factor, and the disruption of HOX/PBX dimer 
formation using the HXR9 peptide has been shown to trigger apoptosis in a wide range of solid 
malignancies both in vitro and in vivo [18-23]. Furthermore, HOX expression has been shown to 
promote a number of aggressive tumour characteristics, including invasion and migration [24], DNA 
repair [25], and the induction of angiogenesis [26]. Consequently, the tumour expression of a 
number of HOX genes has been shown to be related to the survival of cancer patients [27]. 
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Despite a number of excellent reviews on this subject, the HOX expression profiles of different 
cancer types generally remains unclear as it is difficult to directly compare the information in studies 
that have used different techniques to assess HOX expression, and some studies have given 
conflicting results. This review attempts to establish a broad overview of HOX expression in different 
solid malignancies by only including data on the over- or under-expression of HOX genes based on at 
least 2 different techniques (e.g. QPCR and immunohistochemistry), and which has been 
demonstrated in 2 different studies. The findings of this review for head and neck [24, 28-36], 
oesophageal [37, 38], gastric [39, 40], colorectal [41], pancreatic [42], hepatic [41], lung [43-46], 
breast [47], bladder [48, 49], renal [23], prostate [50, 51], and ovarian cancer [52-54] are 
summarized in Fig 1 and Table 1. It is striking that different tumour types show very different 
patterns of HOX expression. For example, gastric tumours tend to show very little HOX gene over-
expression, whilst hepatic tumours exhibit a vastly dysregulated network of HOX genes. It also seems 
clear that different tumour types have radically different HOX gene expression patterns, with the 
notable exception of bladder and prostate tumours (Fig 1). These distinct, tumour-specific 
expression profiles make HOX genes potential markers of CTCs. 
 
HOX genes as CTC markers 
 
As discussed above, CTCs generally make up only a very small proportion blood cells. After excluding 
red blood cells, the majority of remaining cells are lymphocytes and monocytes. Both have 
previously been shown to express HOX genes, and indeed the expression of all 39 HOX genes has 
been studied in different lymphocyte and monocyte populations [55]. This revealed that monocytes, 
T-lymphocytes and B-lymphocytes expressed distinct but also overlapping sets of HOX genes, and 
also that HOX gene expression changed considerably upon activation of the cell types. In contrast, 
very little is known of HOX expression in other myeloid lineages, although previous studies have 
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suggested that HOX genes are generally down-regulated in mature blood cells [56]. In the context of 
possible CTC markers, these data are potentially very useful as they also reveal that a number of 
HOX genes are not expressed in normal lymphocytes or monocytes (Table 2). Despite the reduced 
number of HOX genes available for possible CTC identification, all tumour types appear to present 
with a distinct pattern of non-lymphocytic/monocytic HOX expression, except for bladder and 
prostate tumours (Fig 2). Based on these findings, it seems possible that HOX expression profiles 
could act as a “fingerprint” of specific tumour types, potentially allowing CTC detection without CTC 
isolation. For example, hepatic CTCs might be distinguished by their very high level of HOX 
dysregulation, whilst gastric CTCs appear to be characterized by high levels of HOXA13 expression in 
the absence of other HOX genes. Ovarian and pancreatic cancer is likewise distinguishable by the 
predominant expression of genes from the HOXB cluster, although the former expresses more 
posterior (5’) HOX genes than the latter. It should be noted that the data presented in this review 
are inevitably incomplete with respect to the expression of HOX genes in both cancer and normal 
blood cells. However, it is becoming apparent that there is high degree of differential HOX 
expression between mature blood cells and CTCs, pointing towards a nucleic acid based 
methodology for distinguishing between these cell types. 
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Table 1: HOX gene expression in cancer – stages and comparators 
HOX genes Cancer Disease stage Comparator Reference 
HOXB9 Head and 
neck 
 Immortalized 
normal oral 
keratinocytes, 
normal oral mucosa 
[24] 
HOXA1 Head and 
neck 
 Normal oral 
mucosa 
[28] 
HOXB7 Head and 
neck 
I, II, III, IV Normal oral 
mucosa 
[29] 
HOXD10 Head and 
neck 
Primary, metastatic Immortalized 
normal oral 
keratinocytes, 
normal oral mucosa 
[30] 
HOXB5 Head and 
neck 
N0, N+ Normal oral 
mucosa 
[31] 
HOXA10 Head and 
neck 
I, II, III, IV Normal oral tissue [32] 
HOXD10 Head and 
neck 
 Immortalized 
normal oral 
keratinocytes, 
normal oral mucosa 
[33] 
HOXC5 Head and 
neck 
 Rat normal oral 
tissue 
[34] 
HOXC6 Head and  Normal tissue [35] 
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neck 
HOXA10, A13, B7, C4, 
C8, D9, D10, D13 
Oesophageal 
cancer 
IIa, IIb, III Normal oral 
mucosa 
[37] 
HOXD9 Oesophageal 
cancer 
 None [38] 
HOXA13 Gastric cancer All T stages, metastasis Normal mucosa [39] 
HOXC6 Gastric cancer  Normal mucosa [40] 
HOXA9, B3, B8, B9 Colorectal 
cancer 
pT1, pT2, pT3, pT4 Normal colorectal 
mucosa 
[41] 
HOXA3, A5, A6, A7, 
A9, A10, A11, A13, B1, 
B6, B7, B8, B9, B13, 
C5, C6, C8, C9, C10, 
C11, C12, C13, D1, D3, 
D4, D8, D9, D10 
Hepatic 
cancer 
pI, pII, pIII, pIVa Normal liver tissue 
adjacent to the 
tumour 
[41] 
HOXB2, B5, B6, B7 Pancreatic 
cancer 
Pre-malignant 
pancreatic 
intraepithelial 
neoplasia, 
adenocarcinoma 
Normal tissue [42] 
HOXA1, A5, A10, C6 Non-small cell 
lung cancer 
pTNM: 
pT2(N0/1/2)M0 
pStage: IB/IIB/IIIA 
Normal tissue [43] 
HOXB9 Lung cancer All clinical stages and 
TNM categories 
Normal tissue [46] 
9 
 
assessed 
HOXA1 Small cell lung 
cancer 
Extensive and limited 
disease 
Normal lung alveoli 
epithelium 
[45] 
HOXA6, A13, B2, B4, 
B5, B6, B7, B8, B9, C5, 
C9, C13, D1, D8 
Breast cancer  Non-malignant 
tissue 
[47] 
HOXB13 Bladder 
cancer 
Muscle invasion Non-invasive 
disease 
[49] 
HOXC4, C5, C6, C11 Bladder 
cancer 
 Normal 
uroepithelium 
[48] 
HOXB13 Prostate 
cancer 
 Normal prostate 
tissue 
[50] 
HOXC4, C5, C6, C8 Prostate 
cancer 
Primary tumours, 
metastatic disease 
Normal prostate 
epithelium, benign 
hypertrophy 
[51] 
HOXA10 Ovarian 
cancer 
 Normal ovarian 
tissue 
[52] 
HOXB7, B13 Ovarian 
cancer 
 Normal ovarian 
tissue 
[53] 
HOXB8 Ovarian 
cancer 
Histological stages: 
high, low 
FIGO stages: IIIc, IV 
Normal ovarian 
tissue 
[54] 
HOXA5, A9, B5, C9, D8, 
D9, D10 
Renal cancer  Normal adjacent 
tissue 
[23] 
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Table 2: HOX genes not expressed in normal lymphocytes or monocytes 
 
HOXA HOXB HOXC HOXD 
HOXA1 HOXB1 HOXC5 HOXD4 
HOXA7 HOXB2 HOXC9 HOXD13 
HOXA9 HOXB3 HOXC10  
HOXA11 HOXB5 HOXC11  
HOXA13 HOXB6   
 HOXB7   
 HOXB8   
 HOXB9   
 HOXB13   
 
Figure 1: Summary of HOX gene expression in different solid malignancies. 
Figure 2: Summary of HOX genes expressed in different solid malignancies that are not expressed in 
normal lymphocytes or monocytes. 
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